Medivir terminates the ADAM8 inhibitor project for pancreatic cancer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that it will terminate its ADAM8 inhibitor project for pancreatic cancer. The closure of the project follows a semi-annual review of the company's R&D project portfolio, which deprioritized the project based on data generated during the last six months. As a consequence the license agreement with Cancer Research Technology (CRT) for ADAM8 inhibitors and the collaboration with CRT and TransMIT GmbH will be terminated.    

With the closure of this project, internal resources are transferred to the company's other oncology discovery projects. These projects are focused on the identification of new treatments for hepatocellular carcinoma, pancreatic cancer and other areas of high unmet medical need among cancer patients, and utilize Medivir's core technologies of protease inhibitor design and nucleoside/nucleotide science.

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.